Cartography Biosciences, a San Francisco Bay Area biotechnology company, announced Thursday it raised a $67 million Series B round to propel its first drug prospect into clinical testing. Its lead ...

AstraZeneca has hailed another phase 3 win for its blood pressure drug candidate baxdrostat, boosting its attempts to turn the molecule’s long half-life into a competitive advantage. Baxdrostat, an ...

CHICAGO--(BUSINESS WIRE)--Pritzker Alternative Strategies LP (“PAS” or “the Firm”), today announced it has formed a dedicated family capital investment firm for passive investing in high-quality ...

Financing led by Pfizer Ventures will support advancement of lead program CBI-1214 into a Phase 1 trial, targeted for enrollment in early 2026, and expand next wave of programs from the ATLAS and ...